À PROPOS DE CET ÉPISODE
Brad Wyman’s seen a few things over his 30-year career: the potential of medical imaging, the limits of biomarker development, and the struggles and successes inherent to translational medicine. Join host Colin Miller as Brad shares stories from the front lines of clinical development.
- Why successful biomarkers don’t guarantee clinical success
- Engineers vs. scientists, and how Brad distinguishes between them
- Integrated approaches to marketing and business strategy
- The impact of AI, and where Brad would invest a hypothetical $100M (hint: it’s not AI)
Anglais
États-Unis
TRANSCRIPTION 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
RECHERCHER LES ÉPISODES PASSÉS
Rechercher les épisodes précédents de Fractals: Life Science Conversations.
AUTRES ÉPISODES DANS CE PODCAST
With more than four decades of experience in oncology, cardiovascular imaging, ultrasound, and radioligand therapy, Dr. François Tranquart has helped shape the field of molecular imaging from both sides of the table—first as an academic physician and researcher, and later as an industry leader driv…
Can AI help radiologists see what humans can’t—and speed up drug development in the process?
In this episode of SNiPs, Dr. Ben Larimer joins Bracken CEO Dr. Colin Miller to explore how artificial intelligence and machine learning are redefining what’s possible in molecular imaging. From interpretin…
With more than 30 years of experience spanning global pharma, emerging biotech, and the evolving field of personalized medicine, Bracken Senior Partner Dr. David Krause has helped shape the clinical and regulatory landscape across therapeutic areas—from vaccines and anti-infectives to neuropsychiat…
What if a nasal spray could switch off acute social anxiety in minutes—without systemic side effects?
Shawn Singh, CEO of Vistagen, joins Fractals to explain how pherines work: odorless intranasal molecules that tap the olfactory pathway to flip specific brain circuits on and off.
Highlights from t…
What does it take to lead successful drug development—whether at a global pharma giant or a small biotech start-up?
In this episode of SNiPs, Dr. David Krause joins Bracken CEO Dr. Colin Miller to reflect on three decades of experience spanning large organizations like GSK to fast-moving start-ups.…
Avertissement: Le podcast et les illustrations intégrés sur cette page proviennent de The Bracken Group, qui est la propriété de son propriétaire et n'est ni affilié ni approuvé par Listen Notes, Inc.
MODIFIER
Merci de nous avoir aidé à tenir la base de données de podcasts à jour.
